<DOC>
	<DOCNO>NCT02344641</DOCNO>
	<brief_summary>The study evaluate efficacy heart function improvement type 2 diabetes heart failure patient exenatide , also investigate mechanism exenatide improve heart function .</brief_summary>
	<brief_title>Efficacy Mechanism Exenatide Improving Heart Function Type 2 Diabetes With Heart Failure Patients</brief_title>
	<detailed_description>The study enroll 234 patient type 2 diabetes heart failure . The patient New York Heart Association ( NYHA ) functional class II IV , randomly assign 2 group . One group use exenatide , group control group group 117 patient . At baseline , 3rd day , 28th day patient require complete heart failure examination : plasma N-terminal pro-B-type natriuretic peptide ( NT-proBNP ) , 6-min walking distance , echocardiographic measure , patient quality life ( MLHFQ ) . At end 4-week follow-up , evaluate efficacy heart function improvement treatment exenatide also investigate mechanism exenatide improve heart function .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Diagnosed Type 2 diabetes mellitus 2 . HbA1c 7 % 10 % Fasting plasma glucose ( FBG ) &lt; 10mmol/L 3 . Age 1865 year 4 . NTproBNP level≥ 450 pg/ml 5 . Left ventricular ejection fraction ( LVEF ) &lt; 40 % 1 . Uncorrected primary vascular disease 2. congenital heart disease 3 . Left ventricular outflow obstruction 4 . Myocarditis 5 . Aneurysm 6. uncontrolled severe arrhythmia 7. cardiogenic shock 8. unstable angina , acute myocardial infarction 9 . Severe primary hepatic , renal , hematologic disease 10 . Cr &gt; 194.5 mmol/l K+ &gt; 5.5 mmol/l 11 . Systolic blood pressure ( SBP ) ≥180mm Hg diastolic blood pressure ( DBP ) ≥110mm Hg 12 . Alanine aminotransferase ( ALT ) &gt; 3 time upper normal limit 13 . Patients likely undergo coronary artery bypass graft surgery follow 4 week 14 . Patients undergone likely undergo cardiac resynchronization therapy 15 . Pregnant lactate know 16 . Suspected allergic study drug 17 . Use dipeptidyl peptidase4 ( DPP4 ) glucagonlike peptide1 ( GLP1 ) drug 3 month 18 . Hyperthyroidism Hypothyroidism 19 . Tumor 20 . Received another investigational drug within 30 day prior randomization 21 . Severe mental health condition uncontrolled systemic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>